Oral and intravenous steroids in giant cell arteritis

Clinical and Experimental Ophthalmology

Volumn 31, Issue 3, 2003, Pages 179-182

  Chan, Colin C K ^a   O'Day, Justin ^b  

^a SYDNEY EYE HOSPITAL   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Amaurosis fugax; Giant cell arteritis; Steroids; Temporal arteritis; Visual loss

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ACUTE PSYCHOSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONVALESCENCE; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; GERIATRIC PATIENT; GIANT CELL ARTERITIS; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; ISCHEMIC OPTIC NEUROPATHY; KIDNEY DISEASE; LIPID PEROXIDATION; LIVER NECROSIS; MUSCLE HEMATOMA; OPTIC NERVE DISEASE; PEMPHIGUS VULGARIS; PREVENTIVE MEDICINE; REVIEW; SEIZURE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; TRANSITIONAL BLINDNESS; UNSTABLE ANGINA PECTORIS; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; HUMANS; INJECTIONS, INTRAVENOUS; RECOVERY OF FUNCTION; STEROIDS; TEMPORAL ARTERITIS; VISION;

EID: 0038491503     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2003.00643.x     Document Type: Review

References (31)

1. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80: 355-67.
2. Mack HG, O'Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J Clin Neuroophthalmol 1991; 11: 221-7.
3. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 2001; 85: 1061-4.
4. Liu GT, Glaser JS, Schatz NJ, Lawton Smith J. Visual morbidity in giant cell arteritis. Ophthalmology 1994; 101: 1779-85.
5. Schneider HA, Weber AA, Ballen PH. The visual prognosis in temporal arteritis. Ann Ophthalmol 1971; 3: 1215-30.
6. Aiello PD, Trautman JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100: 500-555.
7. Matzkin DC, Slamovits TL, Sachs R, Burde RM. Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant cell arteritis. Ophthalmology 1992; 99: 69-71.
8. Model DG. Reversal of blindness in temporal arteritis with methylprednisolone. Lancet 1978; 1: 340.
9. Diamond JP. Treatable blindness in temporal arteritis. Br J Ophthalmol 1991; 75: 432.
10. Cornblath WT, Eggenberger ER. Progressive visual loss from giant cell arteritis despite high dose intravenous methylprednisolone. Ophthalmology 1997; 104: 854-8.
11. Slavin ML, Margolis AJ. Progressive anterior ischaemic optic neuropathy due to giant cell arteritis despite high dose intravenous corticosteroids. Arch Ophthalmol 1988; 106: 1167.
12. Bracken MB, Shepard MJ, Collins WF et al. A randomised, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl J Med 1990; 322: 1405-11.
13. Sabir S, Werth VP. Pulse glucocorticoids. Dermatol Clin 2000; 18: 437-45.
14. Hall ED. High-dose glucocorticoid treatment improves neurological recovery in head-injured mice. J Neurosurg 1985; 62: 882-7.
15. Young W, Flamm ES. Effect of high-dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg 1982; 57: 667-73.
16. Anderson DK, Means ED, Waters TR, Green ES. Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J Neurosurg 1982; 56: 106-13.
17. Toth GG, Westerlaken BC, Eilders M, Laseur M, Jonkman MF, Uges DRA. Dexamethasone pharmacokinetics after high-dose oral treatment for pemphigus. Ann Pharmacother 2002; 36: 1109.
18. Stubbs SS, Morrell RM. Intravenous methylprednisolone sodium succinate: Adverse reactions reported in association with immunosuppressive therapy. Transplant Proc 1973; 5: 1145-6.
19. McDougal BA, Whittier FC, Cross DE. Sudden death after bolus steroid therapy for acute rejection. Transplant Proc 1976; 8: 493-6.
20. Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med 1981; 95: 781-2.
21. Bocanegra TS, Castaneda MO, Espinoza LR et al. Sudden death after methylprednisolone pulse therapy. Ann Intern Med 1981; 95: 1-22.
22. Thompson JF, Chalmers DH, Wood RF et al. Sudden death following high dose intravenous methylprednisolone. Transplantation 1983; 36: 594-6.
23. Suchman AL, Condemi JJ, Leddy JP. Seizure after pulse therapy with methylprednisolone. Arthritis Rheum 1983; 26: 117.
24. Belmonte MA, Cequire A, Roig-Escofet D. Severe ventricular arrhythmia after methylprednisolone pulse therapy in rheumatoid arthritis. J Rheumatol 1986; 13: 477-9.
25. Doezema D. Anaphylaxis following administration of intravenous methylprednisolone sodium succinate. Am J Emerg Med 1987; 5: 42-4.
26. Gardiner PVG, Griffiths ID. Sudden death after treatment with methylprednisolone BMJ 1990; 300: 125.
27. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993; 269: 2110-12.
28. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: A double blind study. Acta Neurol Scand 1998; 97: 370-73.
29. Marcocci C, Bartalena L, Tanda ML et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Grave's ophthalmopathy. J Clin Endocrinol Metab 2001; 86: 3562-7.
30. Seiter S, Ugurel S, Tilgen W, Reinhold U. High dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 2001; 202: 230-34.
31. Chevalet P, Barrie JH, Pottier P et al. A randomised, multicenter, controlled trial using intravenous pulses of methyl-prednisolone in the initial treatment of simple forms of giant cell arteritis: A one year follow up study of 164 patients. J Rheum 2000; 27: 1484-91.